PlatinumResistant

<!-- Name:DistributionId Value:8846911 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

Topline data expected mid-2023Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company…

The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial ONC-392 is the first known acid pH-sensitive anti-CTLA-4 mAb that interacts…

Topline data from UPLIFT expected in mid-2023Targeting potential Biologics License Application (BLA) submission by the end of 2023 CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a…

TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced top-line data from the…

MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic…

Addition of relacorilant to nab-paclitaxel reduces risk of death by 33 percent compared to treatment with nab-paclitaxel alone (p-value: 0.066), without increased side effectsExcluding patients (i) who had not responded to even their first…

Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021Results show benefit experienced by women with recurrent…